A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

Who May Qualify: - Japanese male or female participants 18 years of age or older at the time of willing to sign a consent form - Diagnosed with schizophrenia according to the DSM-5® - Judged by the investigator to be clinically stable for at least 8 weeks prior to screening - PANSS total score of 80 or less and CGI-S score 4 or less at both screening and baseline - No changes in antipsychotic medication for at least 6 weeks before screening (excluding minor dose adjustments for tolerability) Who Should NOT Join This Trial: - History of psychiatric hospitalization within 8 weeks prior to screening - Treatment-resistant to antipsychotic therapy (ie, within 1 year to screening, despite administration of two or more marketed antipsychotics at appropriate doses for at least 4 weeks \[28 consecutive days\] in accordance with the package insert, psychiatric symptoms did not improve) - History of treatment with clozapine - Unwillingness, before or during the trial period, to comply with the requirements for prior and concomitant medications/therapies as specified in the protocol or use of prohibited medications at screening or baseline as specified in the protocol. Always talk to your doctor about whether this trial is right for you.